Momenta Pharmaceuticals, Inc.
Quick facts
Phase 3 pipeline
- M923 · Immunology
M923 is a monoclonal antibody that targets and modulates IgG glycosylation to enhance immune function.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Momenta Pharmaceuticals, Inc.
What is Momenta Pharmaceuticals, Inc.'s pipeline?
Momenta Pharmaceuticals, Inc. has 1 drugs in Phase 3, 1 in Phase 2, 3 in Phase 1. Late-stage candidates include M923.
Related
- Sector hub: All tracked pharma companies